Timeline Of Russian Sputnik V Covid-19 Vaccine, Approved For Emergency Use In India
by Bhaswati Guha Majumder - Apr 13, 2021 03:55 PM
Russian Covid-19 vaccine Sputnik V
Snapshot
A quick look at the journey of Russian Covid-19 vaccine Sputnik V, from its early days till its entry in India.
Russia s Covid-19 vaccine is the worldâs first to be registered based on the human adenoviral vector-based platform.
Now, India has become the sixtieth country to approve the two-dose Sputnik V vaccine after the Drugs Controller General of India (DCGI) gave the green signal.
Here is the journey of Sputnik V and its entry into India.
REUTERS/Danish Siddiqui
Latest coronavirus news as of 5pm on 12 April
As millions gather to celebrate Kumbh Mela, India’s coronavirus cases surge, overtaking Brazil in total number of infections
India reported a record increase of 168,912 new coronavirus cases on 12 April, bringing the country’s total number of cases since the start of the pandemic to about 13.53 million. India’s tally is now the second-highest in the world, narrowly overtaking Brazil, but remaining below the 31.2 million cases reported so far in the US.
Advertisement
According to estimates from Johns Hopkins University, infections in India are on course to double in two months. Some officials have expressed concerns about crowding at religious festivals and political rallies. In the northern city of Haridwar almost a million people gathered by the Ganges river on 12 April to participate in the Hindu festival Kumbh Mela. “The police are continuously appealing to people to maintain social distancing,
Biostatistics.
The board also holds a position for a lay person (non-healthcare professional) to represent consumer interests.
The purpose of the board is to provide expert advice on the safety of COVID-19 vaccine(s) during the national roll-out. It is intended that the board will provide advice to the Centre for Adverse Reactions Monitoring (CARM), Medsafe, the COVID-19 immunisation programme, and Ministry of Health on:
the interpretation of the information;
the significance of the information in relation to the risk-benefit profile of the vaccine;
whether an issue needs referral to the Medicines Adverse Reactions Committee for advice or to Medsafe for consideration of possible regulatory intervention; and
Stephen Zenner/SOPA Images/Shutterstock
Latest coronavirus news as of 5pm on 9 April
The EU’s medicines regulator is reviewing a small number of reports of rare blood clots in people who received the Johnson & Johnson vaccine
The European Union’s medicines regulator is reviewing four reported cases of rare blood clots associated with low levels of platelets – small particles in the blood that normally help in clotting – including one case which was fatal, in people who received the Johnson & Johnson covid-19 vaccine. The European Medicines Agency (EMA) is also reviewing five reported cases of a bleeding condition, called capillary leak syndrome, in people who received the Oxford/AstraZeneca covid-19 vaccine. “At this stage, it is not yet clear whether there is a causal association” between the vaccines and the reported conditions, the EMA said. Both the Oxford/AstraZeneca and Johnson & Johnson vaccines are based on viral vector technologies, which use inactivated cold
AstraZeneca Moves From Favored Child To Problem Child Among Vaccines AstraZeneca Moves From Favored Child To Problem Child Among Vaccines But at around 5 the next morning, Pangalos was jolted out of bed in the U.K. by a call from AstraZeneca Chief Executive Officer Pascal Soriot, ringing from Australia to ask what on earth was happening.
Updated: April 08, 2021 2:01 pm IST
In span of a year, Astra has gone from favored child to problem child in family of coronavirus vaccines.
Mene Pangalos, head of biopharmaceuticals research for AstraZeneca Plc, went to bed on Monday, March 22, feeling good for the first time in a while. After working around the clock through the weekend, he d just announced better-than-expected interim results from the company s large U.S. vaccine trial: The shot was safe and 79% effective at preventing cases of symptomatic Covid-19. Positive news, at last, after months of questions about everything including safety and supply shortfalls.